ABOUT RE-VANA

Re-Vana Therapeutics is an ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma.

Our delivery platforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using our platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 4-6 months or more.

Our injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 4-6 months or more. Our preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 4-6 months or more.

The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.

CONTACT US

United Kingdom
T: +44 (0) 28 9097 5814
E: info@re-vana.com

USA

T: +1 (813) 323 1438
E: mor.revana@gmail.com

Mailing
Re-Vana Therapeutics Ltd 
McClay Research Centre
97 Lisburn Road
Belfast, BT9 7BL
United Kingdom

Re-Vana Therapeutics Inc.
1027 South Dakota Ave
Tampa, FL 33606
USA

OPPORTUNITIES


Check back for opportunities.

PARTNERSHIPS

Re-Vana collaborates and is open to business development partnerships to deliver both small and large molecules with our technology platforms.

To discuss please contact Michael O’Rourke CEO on (+1) 813 323 1438  (Tampa Florida) or mor.revana@gmail.com

Our Products

EyeLief™

EyeLief™ is a novel photocrosslinked sustained-release preformed biodegradable implant delivering large and small therapeutics for 4-6 months or more.

OcuLief™

OcuLief™ is a novel photocrosslinked biodegradable gel implant for the sustained release of large and small therapeutics for 4-6 months or more.

NICOX ENTERS RESEARCH COLLABORATION WITH RE-VANA THERAPEUTICS

Re-Vana's technology offers us additional opportunities, alongside our recently announced collaboration with pSivida, to explore the potential for sustained-release delivery of our novel, next generation of stand-alone NO-donors. EyeLief(TM) technology has a number of unique properties that have shown promise in the delivery of drugs for the reduction of IOP. We look forward to working with Re-Vana on this innovative research endeavor.
Michael Bergamini, Executive Vice President and Chief Scientific Officer, Nicox

RE-VANA'S DESIGN STRATEGY

The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.

CONTACT US

United Kingdom
T: +44 (0) 28 9097 5814
E: info@re-vana.com

USA

T: +1 (813) 323 1438
E: mor.revana@gmail.com

Mailing

Re-Vana Therapeutics Ltd
McClay Research Centre
97 Lisburn Road
Belfast, BT9 7BL
United Kingdom

Re-Vana Therapeutics Inc.
1027 South Dakota Ave
Tampa, FL 33606
USA